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Angiotensin II modulates cell growth-related events and synthesis
of matrix proteins in renal interstitial fibroblasts
MARTA RUIZ-ORTEGA and JEsus EGID0
Renal Unit, Fundación Jiménez DIaz, Universidad Autónoma, Madrid, Spain
Angiotensin H modulates cell growth-related events and synthesis of
matrix proteins in renal interstitial fibroblasts. The renin-angiotensin
system seems to play an important role in the pathogenesis of renal
interstitial fibrosis. However, the potential direct effects of angiotensin It
(Ang II) on cultured renal flbroblasts have been little studied. We have
observed that rat renal interstitial fibroblasts (NRK 49F cell line) possess
AT1 receptors coupled to intracellular calcium mobilization. Exposure of
these cells to Ang II induced several short and long growth-related
metabolic events mediated by the AT1 receptor, including c-fos gene
expression, changes in cell cycle and cell proliferation. Activation of
interstitial fibroblasts by Ang II could also contribute to extracellular
matrix accumulation. Stimulation with Ang II increased mRNA expres-
sion of TGF-131, fibronectin and type I collagen. In fact, Ang II enhanced
fibronectin production via AT1 receptors by a process depending on
autocrine TGF-p secretion. The mechanism of some Ang II actions
(calcium mobilization and fibronectin production) depended on protein
kinase C and tyrosine kinase activation. We further investigated whether
renal fibroblasts could express some components of the renin-angiotensin
system. These cells constitutively expressed the angiotensinogen gene that
was up-regulated by Ang II. Collectively, these results indicate that in
renal interstitial fibroblasts Ang II causes hyperplasia and extracellular
matrix production via the AT1 receptor. Ang II may initiate a positive
feedback regulation of fibroblasts growth, inducing the expression of
TGF-J31 and angiotensinogen genes. Ang II, acting directly on interstitial
fibroblasts, may be implicated in the pathogenesis of renal fibrosis.
Fibroblasts are the main effector cells of renal interstitial
fibrosis. Under normal conditions only a small proportion of these
cells participate in the synthesis and deposition of matrix proteins,
mainly type I collagen [1]. However, in pathological conditions,
fibroblasts proliferate, migrate and synthesize growth factors and
matrix proteins [2]. The development of interstitial fibrosis has
been attributed to the release of cytokines by infiltrating mono-
nuclear cells and tubular interstitial cells. These cytokines, acting
on fibroblasts, could induce proliferation, recruitment of mono-
nuclear cells and extracellular matrix synthesis [3, 4].
Recent data suggest that the renin-angiotensin system could
play a certain role in the pathogenesis of glomerular and intersti-
tial fibrosis [5—7]. Treatment with angiotensin converting enzyme
inhibitors and angiotensin receptor antagonists decreased tubulo-
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interstitial lesions in several models of renal injury [8—12]. Acti-
vation and redistribution of some components of renin-angioten-
sin system have also been demonstrated in some of these models,
suggesting that this system could be associated with cell growth
changes and sclerosis [13—15]. Moreover, interstitial changes have
been observed in hypertension-induced renal injury and in in vivo
systemic Ang 11 infusion, both situations characterized by mono-
nuclear cell recruitment, proliferation of interstitial cells, and
deposition of matrix proteins leading to renal interstitial fibrosis
[16, 17]. However, a direct effect of Ang II on renal interstitial
fibroblasts independently from secondary hemodynamic actions,
which could explain the above-described processes, has not been
studied.
Angiotensin II may act as a growth factor for several renal cells.
In mesangial cells and tubular epithelial cells this peptide pro-
motes growth changes and synthesis of extracellular matrix pro-
teins. Some of these effects seem to be mediated by the release of
growth factors, such as transforming growth factor-/3 (TGF-13) [7,
18]. TGF-/3 plays an important role in the pathogenesis of renal
diseases [19] and has widespread effects on the turnover of
extracellular matrix proteins [20].
In this work we have studied the potential effect of Aiig II on
growth-related cellular events in renal interstitial fibroblasts. To
test this hypothesis, we first characterized whether renal fibro-
blasts express Ang II receptors and the intracellular signaling
evoked by their stimulation. Secondly, we evaluated whether Ang
II regulates fibroblast proliferation and the synthesis of extracel-
lular matrix and TGF-13, as well as the mechanisms and the
receptor type involved in these phenomena. Finally, we tested
whether these cells could contribute to local Ang II generation
focusing on angiotensinogen mRNA expression.
METHODS
Materials
All culture reagents were purchased from Gibco BRL (Paisley,
Scotland, UK). Ang 11 was obtained from Calbiochem. Dup753
(ATI receptor antagonist) was provided by Dupont (Madrid,
Spain) and PD123177 (AT2 receptor antagonist) by Parke Davis
(Barcelona, Spain). [35S]-Methioninc (1000 Ci/mmol), -
[32P]dCTP (3000 Ci/mmol), a-[32P]ATP (1200 Ci/mmol) and
1251-[Sar',Ile8]Ang II were purchased from Amersham (Bucking-
hamshire, UK). Primers for RT-PCR studies were obtained from
Genosys Biotechnology (Cambridge, England, UK). Polyclonal
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anti-fibronectin (FN) antibody was obtained in rabbits by immu-
nization against human FN [211. Monoclonal mouse anti-TGF-f31
antibody and recombinant human TGF-/31 were obtained from
Immugenex (Los Angeles, CA, USA). The rest of chemicals
employed were from Sigma (St Louis, MO, USA).
Cell cultures
The cell line NRK 49F (ATCC:CRL157O; American Type
Culture Collection, Rockville, MD; USA) is derived from rat
kidney fibroblasts. Cells were grown in RPMI with 5% FCS
(Gibco) at 37°C in the presence of 5% CO2.
Determination of angiotensin II receptors
Receptor binding studies were performed on subconfluent
monolayers of fibroblasts, cultured in 12-well plates, using 125J
[Sar',11e5]Ang II. Cells were maintain for 18 hours in serum-free
RPMJ, and after, in RPM! with 0.5% (wt/vol) of BSA for one
hour. Then cells were incubated with '251[Sar1,11e8]Ang 11(0.1
nM). Competition studies were performed using either Ang II or
the receptor subtype-specific nonpeptide antagonist [22] DUP753
(AT1 specific) or PD123177 (AT2 specific) at various concentra-
tions (102 to io M). Nonspecific binding was determined in
the presence of 1000-fold excess of unlabeled Ang II and was less
than 10% of the total cell bound radioactivity. Binding parameters
(Kd and number sites/cells) were calculated using the Instat
program. After incubation for three hours at 4°C (equilibrium
binding achieved), cells were washed twice with ice-cold phos-
phate saline (PBS) to remove unbound compound. Then cells
were solubilized in 1 M NaOH/0.1% Triton X-100. Radioactivity
in cell lysates was determined in a gamma counter. Specific
binding was calculated as the difference between total and
nonspecific ligand bound.
Measurement of intracellular free calcium
Measurement of calcium mobilization was made as previously
described [231. Monolayer cells grown on 13 mm diameter crystal
coverslips were incubated in serum-free medium during the last
18 hours before the experiment. The cells were then washed and
loaded with the fluorescence Ca2 indicator fura-2 acetometoxy
ester (2 jIM) in RPMI-HEPES for 60 minutes at 37°C, and
incubated again for 30 minutes in a fura-2-free medium for
intracellular dye cleavage. Cells were then rinsed twice with
Krebs-Hensleit-HEPES buffer (KHH) (130 mtvi NaCl, 5.3 mM
KC1, 1 mM MgSO4, 2 ifiM CaC12, 1.2 mi NaH2PO4, 20 mM
HEPES, 5.5 mrvi glucose, and 0.5% BSA, pH 7.3), and coverslips
were mounted in a quartz cuvette with 1 ml of KHH buffer at
37°C. Substances prewarmed in KHH buffer were added directly
to the cuvette. Changes in intracellular calcium ([Ca2]) were
continuously monitored by recording changes in the fluorescence
ratio at 510 nm, with the excitation at 340/380 nm in a spectroflu-
orometer at 37°C (model LS-50; Perkin-Elmer Corp., Norwalk,
CT, USA). In some experiments, extracellular Ca2 was depleted
from the medium by addition of 3 to 5 msi EGTA just before the
fluorescence analysis. In these experiments, after addition of Ang
II (10 M) and when baseline returned to control levels, Ca2
was replaced in the medium to 2 m of final concentration. To
characterize intracellular signal systems, cells were preincubated
with the protein kinase C (PKC) inhibitor, staurosporine (10—6 M,
30 mm), or the tyrosine kinase inhibitor, genistein (10—s M, 60
mm). To determine the angiotensin receptor type involved in
calcium response, cells were preincubated with DUP753 (AT1
specific; 10 M, 30 mm) or PD123177 (AT2 specific; i0 M, 30
mm).
Cell-cycle analysis by fluorescence-activated cell sorting
For determination of cell size and DNA content, subconfluent
cells grown in 75 cm2 petri dishes were incubated in a serum-free
medium for 48 hours to make them quiescent. Then cells were
incubated during 24 hours with Ang II (10—v M) and 10% FCS as
the positive control. At the end of the incubation period, the cells
were washed three times with PBS and trypsin. After centrifuga-
tion, the cellular pellet was treated with 100 jIg/ml ribonuclease A
and DNA was stained with 100 jtg/ml propidium iodide in 0.005%
Nonidet P-40. The stained specimen was kept in the dark at 4°C
before flow cytometry. Cells were sieved to remove dead cells
and/or cellular debris. Data were analyzed with the EPICS-C flow
cytometer (Coulter, Hialeah, FL, USA) using the PARA-1 pro-
gram [241 and represented as either contour plots or histograms.
The percentage of cells in the Go, S and G2 + M phases, mean
channel number and coefficient of variance (CV) for relative size
and DNA content were obtained from histograms after computer
analysis.
Measurement of cellular proliferation
The effect of Ang II on cell proliferation was determined by
methylene blue assay [251. Quiescent subconfluent cells, grown on
96-well plates, were incubated for 24, 48 and 72 hours in serum-
free medium with daily doses (every 24 hr) of Ang II (range i0
to 10_il M). For experiments with Ang II receptor antagonists,
cells were preincubated with DUP753 (10" M, 30 mm) or
PD123177 (10—i M, 30 mm) before the addition of i0 M Ang II.
After the incubation period, cells were washed with PBS and
fixed. Cells were stained with methylene blue in 0.01 M Borate
buffer. The absorbance was measured at 650 nm in a microplate
photometer.
RNA isolation, Northern blot and PCR assays
The expression of transcripts for AT1 receptor, c-fos, extracel-
lular matrix proteins and TGF-/31 was determined using Northern
blot analysis. The angiotensinogen gene expression was studied by
a semiquantitative RT-PCR technique.
Northern blot analysis. Quiescent confluent fibroblasts, grown in
75 cm2 petri dishes, were stimulated in a serum-free medium.
After the incubation period, total RNA was extracted by the
Chomczynski and Sacchi method [26] and quantitated by absor-
bance at 260 nm. Northern blot analysis was performed as
previously described [27]. The eDNA probes used were: c-fos
(ATCC#), (cil)I (Hf677) and (al)IV (pCVIV-1-PE16) collagens,
28S, rat FN (SR270) and murine TGF-/31, obtained as previously
described [27], and labeled with a-[32P]dCTP. The rihoprobe of
the AT1 receptor (kindly provided by Dr. M. Martincz-Maldo-
nado, originally cloned by Murphy et al [28]) was used as the
antisense cRNA from linearized plasmid with Hindill using SP6
promotor and labeled with a-[32P]-ATP. Blots were prehybridized
for four hours at 42°C in hybridization solution (50% formamide,
1% SDS, 5 x SSC, lx Denhardt's solution, 0.1 mg/mI denatured
salmon sperm DNA and 50 m sodium phosphate buffer, pH 6.5)
and hybridization was carried out at 42°C overnight with 20%
dextran sulfate and [ci-32P]-denatured probe. The filters were
washed using a 2 x SSC, 0.1% SDS, at room temperature for 30
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minutes and then twice with 0.2 >< SSC, 0.1% SDS, at 55°C for 15
minutes. For the AT1 receptor, prehybridization and hybridiza-
tion were carried out at 60°C in modified solution (hybridization
mixture with 8X Denhardt's solution and 1 mai EDTA), and the
filters were washed first at 65°C and finally at 70°C, in the same
conditions as described above. Autoradiography was performed
using standard methods.
Reverse transcription and semiquantitative PCR analysis. Total
RNA was reverse transcribed to single-stranded eDNA by incu-
bation with a reverse transcription mixture (5 mvt MgCl2, 10 mM
Tris-HCI pH 8.8, 50 mivi KCI, 0.1% Triton X-100, 1 mM dNTPs
mixture, 20 U rRNAsin ribonuclease inhibitor, 15 U AMV reverse
transcriptase and 50 ng random primers) at 42°C for 30 minutes
following the instructions of the manufacturer (Promega). PCR
analysis for angiotensinogen and Glyceraldehyde 3'-phosphate
dehydrogenase (G3PDH) was conducted in the following condi-
tions (1 mm at 63°154°C, respectively, to allow annealing of the
primers, 3 mm at 72°C for primer extension, and I mm at 94°C to
denature the double-stranded DNA). The following primers were
used for rat angiotensinogen [291: (antisense) 5'-CCAGCCGG-
GAGGTGCAGT-3' and (sense) 5'-TTCAGGCCAAGACCT-
CCC-3', that yielded products of 308 base-pair. G3PDH was used
as an internal control and the following primers were used [30]:
(antisense) 5'-ATACTGTTAC1TATACCGATG-3' and (sense)
5 '-AATGCATCCTGCACCACCAA-3' that yielded products of
515 bp. Both amplifications were done for 20, 30, 35, and 40 cycles
in order to establish the linearity of the reaction. In all experi-
ments, the presence of possible contaminants was checked by
control reactions in which amplification was carried out in com-
plete reaction mixture lacking template DNA or with RNA
samples from RT reactions done in the absence of AMV reverse
transcriptase. The DNA products from the PCR reactions were
analyzed on a 1.5% agarose gel or a 4% polyacrylamide/urea gel
in Tris-borate EDTA buffer. The gels were dried and exposed for
autoradiography.
Autoradiograms were scanned using the Image Quant densi-
tometer (Molecular Dynamics, Sunnyvale, CA, USA). Results
were expressed as arbitrary densitometric units relative to 28S
intensity bands (Northern blot) and G3PDH (RT-PCR).
Determination of fibronectin synthesis
New fibronectin (FN) synthesis was measured by metabolic
labeling with [35S]-Methionine and immunoprecipitation with
anti-FN antibodies [31]. Quiescent cells grown in 24 well plates,
were incubated in methionine-free culture medium RPMI with 20
jiCi/ml of [35S]-methioninc and stimuli. After 24 hours, medium
was collected and cells were lysed with extraction buffer (50 mM
Tris-HCI, 150 mrvi NaC1, 0.5% Triton X-100, 2 mrvi PMSF, 2 mM
EDTA and 5 mM NEM, p11 7.4). Aliquots of the supernatants
(diluted 1:10 in extraction buffer) and cell lysates were immuno-
precipitated with an excess of anti-FN antibody (50 tg) for 16 to
18 hours at 4°C. After this incubation, immune complexes were
recovered by addition of protein A-Sepharose beads (Pharmacia,
Uppsala, Sweden), and incubated for one additional hour. Beads
were washed in extraction buffer. FN was released by heating at
100°C for five minutes in electrophoresis sample buffer and
analyzed under denaturing conditions in 7.5% SDS-polyacryl-
amide gels. The gels were handled by fluorography techniques and
autoradiography was performed by standard methods. In order to
normalize FN production to cell number, samples aliquots (20 1.d)
of cell lysates were taken for determination of DNA content. As
a negative control for immunoprecipitation, isotopic normal rab-
bit IgG (30 jxg/ml) was used.
For experiments with Ang II receptor antagonists, cells were
preincubated with DUP753 (10—6 M, 30 mm) or PD123177 (10
M, 30 mm). To further investigate the mechanism of FN synthesis,
cells were treated with the inhibitors of RNA and protein
synthesis, actinomycin D (Act D; 50 jtg/ml) and cycloheximide
(CHX; 1 g/ml), respectively, in control and Ang Il-stimulated
cells (i0— M Ang II, added 30 mm after the inhibitors). To
characterize intracellular signal systems, cells were preincubated
for 30 minutes with the inhibitor of PKC, staurosporine (Staur.;
108 M) or tyrosirle kinase, genistein (Genist.; 10-6 M) before the
addition of io M Ang II. To determine the role of endogenous
TGF-p, cells were coincubated with 10 pg/mI of anti-TGF/3
neutralizing antibody and i0 M Ang II. Recombinant human
TGF-p (50 pM) was employed as positive control for FN synthesis.
Statistical analysis
Results are expressed as the mean SEM. Significance was
established using a Student's t-test and analysis of variance.
Differences were considered significant if the P value was less
than 0.05.
RESULTS
Renal interstitial fibroblasts possess AT1 receptors
We first examined whether rat renal interstitial fibroblasts
(NRK cell line) express Ang II receptors. Binding studies were
performed by using 0.1 nrvt 1251-[Sar',11e8]Ang II in subconfiuent
cells, In preliminary studies we determined binding time and
temperature. Binding of '251-[Sar1,Ile8]Ang II increased linearly
for up to one hour and remained constant for an additional six
hours at 4°C. At this temperature there was no internalization of
the complexes, a process that was found at 37°C (data not shown).
The competition binding of '251-[Sar1,11e8]Ang II by unlabeled
Ang II indicated the existence of a specific binding in renal
interstitial fibroblasts with a K of 0.23 nM and around 54000
sites/cell (Fig. 1A). Ang II receptors have been described in
medullary interstitial cells [32] and in rabbit renal interstitial
fibroblasts [33]. In interstitial mice fibroblasts (TFB cell line, [34]),
we also determined the Ang II binding sites showing similar
results to those described for rat cells (data not shown). More-
over, the affinity of these receptors (Kd of 0.23 nM) in rat renal
fibroblasts was similar to that reported for AT1 receptors in
fibroblasts of different tissues (cardiac [35, 36] and skin [37]), in
vascular smooth muscle cells [38] and mesangial cells [39].
To determine the receptor subtype present in renal fibroblasts,
competition studies were made in the presence of two Ang II
specific nonpeptidic receptor antagonists (DUP753, AT1 receptor
antagonist and PD123177, AT2 receptor antagonist). Fibroblasts
were incubated with '25l-[Sar1,11e8]Ang II and increasing concen-
trations of DUP7S3 and PD123177 for three hours at 7°C (Fig.
1A). The AT1 receptor antagonist, DUP753, completely displaced
the bound labeled compound. By contrast, the AT2 receptor
antagonist, PD123177, did not displace the labeled peptide,
though at concentrations higher than 10 M a slight effect was
noted. A similar effect has been observed in cardiac fibroblasts,
hut it was not clear whether this displacement of the radioligand
C)
C
with high concentrations of PD 123177 was a specific competition
or a crossover interaction with the AT1 receptor [35].
To confirm the presence of AT1 receptors in rat renal intersti-
tial fibroblasts, we determined whether these cells express AT1
receptor mRNA. Total RNA was extracted and analyzed by
Northern blot using a riboprobe for AT1 receptor gene cloned
from vascular smooth muscle cells [28]. Fibroblasts expressed a
transcript of 2.35 kb (Fig. 1B), corresponding to AT1 receptor
mRNA described in vascular smooth muscle cells [281. Together,
these data indicate the presence of Ang II receptors in renal
interstitial fibroblasts.
Angiotensin II receptors are linked to calcium mobilization
Angiotensin II increases calcium concentration in mesangial
cells [40], tubular epithelial cells [41] and cardiac fibroblasts [361,
though the intensity of the response varied among the cell types.
Intracellular Ca2 mobilization was determined by continuous
monitoring of fluorescence intensity [23]. Cells were loaded with
fura-2/AM and the emitted fluorescence in response to Ang II
stimulation was measured. Angiotensin II (l0 to 10'' M)
evoked a rapid rise in intracellular free calcium. The transient
increase in Ca2 was dramatic at higher concentrations of Ang II
(Fig. 2).
The next point of our study was to investigate the mechanism of
calcium mobilization in response to Ang II. After chelation of
extracellular Ca2 by EGTA, Ang II (10—v M) still elicited an
increase in intracellular Ca2 concentrations (Fig. 3), though the
decay to resting levels was faster than in the presence of extracel-
lular Ca2 . When the baseline returned to control levels, Ca2
was replaced in the medium (2 m of final concentration) and an
increase in fluorescence was observed, probably due to the influx
10 20 30 40 50
Time, seconds
Fig. 2. Stimulation of interstitial fibroblasts with angiotensin II induces
calcium increase in a dose-dependent manner. Cells in cover slips were
loaded with fura-2 and stimulated with Ang II (106 to 10- M).
Continuous fluorescence monitoring of [Ca2] levels was performed.
Values are ratios of emitted fluorescence at 340/380 nm excitation. A
representative experiment of 6 to 9 experiments is shown.
of Ca2 from the extracellular environment. These data suggest
that the transient increase in intracellular Ca2 may result from
both mobilization of intracellular Ca2 stores and Ca2 influx
across the membrane. The observation that Ang II stimulated a
calcium transient event in the absence of extracellular calcium
suggests that Ang II could mobilize calcium from intracellular
stores via inositol thriphosphate and therefore activate phospho-
lipase C, presenting the signaling characteristic of Ang II re-
sponses in several cell types [7, 35, 36, 401.
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Fig. 1. Renal interstitial fibroblasts possess angiotensin H binding sites. (A) Displacement of '251[Sar',11e8]Ang II binding from renal fibroblasts.
Competition of the binding of '251[Sar',11e8]AngII by increasing concentrations of unlabeled Angli (U), Dup753 (A) or PD123177 (+). Data represent
mean SCM from 3 independent experiments made by duplicate. (B) Renal interstitial fibroblasts express AT, mRNA. Total RNA was extracted from
unstimulated cells and hybridized with the AT, receptor riboprobe. Representative Northern blot showing that fibroblasts express a mRNA transcript
of 2.35 Kb corresponding to the AT, receptor.
A
12 11 10 9 8 7 6 5 4
E
0
U-
C,,
U-
1.5
1.4
1.3
1.2
1.1
Ang II 1O—6M
107M
tO—8M
101 1M
E
C
C,)
U-
C
C')Li
E
C
C')U-C
C,)U-
A
1501
0
C
10 20 30
Time, seconds
0
D
10 20 30
Time, seconds
Ruiz-Ortega and Egido: Ang II and interstitial fibroblasts
B
1.5 1.5
1.4 1.4
1.3 1.3
1.2 1.2
1.1 1.1
1 1
1.5 1.5
1.4 1.4
1.3 1.3
1.2 1.2
1.1 1.1
1 1
1.5 1.5
1.4 1.4
1.3 1.3
1.2 1.2
1.1 1.1
1 1
Time, seconds Time, seconds
Fig. 3. Molecular characterization of calcium mobilization in angiotensin Il-stimulated fibroblasts. Control and pretreated cells were loaded with
fura-2 and fluorescence measurements after addition of 1O vi Ang II were performed. Experimental details are given in the Methods section. (A) In
control cells io- M Ang II increased [Ca2J1. (B) When extracellular Ca2 was depleted from the medium by addition of EGTA, a reduction in Ang
11-induced Ca2 increase was observed. When [Ca21 returned to control levels, a final concentration of 2 mvi Ca2 was added (indicated by an arrow).
Effect of PKC (C) and tyrosine kinase (D) inhibitors. Role of AT1 receptors; in the presence of DUP753 (AT1 antagonist), Ang TI-induced Ca2
mobilization was blocked (E), while no effect was observed with PD123177 (AT2 antagonist) (F).
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Other second messenger pathways, elicited after Ang IT trans-
membrane signaling, include activation of PKC and tyrosine
kinase phosphorylation [42, 43]. For this reason, we wondered
whether the activation of these kinases was involved in the
calcium mobilization yielded by Ang II in renal interstitial
fibroblasts. Cells were preincubated for 30 minutes with the
inhibitors of PKC and tyrosine phosphorylation, staurosporine
(10—6 M) and genistein (10—s M), respectively, before the
measurement of Ca2 mobilization. Treatment with both
agents did not affect cell viability. As shown in Figure 3, both
inhibitors caused a marked reduction in Ca2 rise in Ang
Il-stimulated cells (65% and 55% vs. Ang II alone, respectively,
N = 6, P < 0.05). Therefore, these results suggest that
activation of PKC and tyrosine phosphorylation are involved in
Ang IT-induced calcium mobilization.
To determine the receptor type involved in Ang TI-induced
Ca2 response, cells were preincubated for 30 minutes with AT
receptor antagonists, DUP753 (106 M) and PD123177 (10 M).
The presence of AT1 antagonist blocked Ang IT-induced Ca2
mobilization (Fig. 3), while the AT2 antagonist did not affect the
kinetics of Ca2 mobilization. These results suggest that AT1
receptors presented in renal interstitial fibroblasts are coupled to
intracellular calcium mobilization.
Angiotensin II elicits cell hyperplasia, but not hypertrophy, via
AT1 receptors
Angiotensin II is now considered to be a renal growth factor,
however, its effects on cell growth depend on the cell type studied.
Ang II induced hypertrophy in tubular epithelial cells [18], while
most authors found a hyperplasic response in mesangial cells [7].
Thus, we were interested in whether Ang IT could modulate the
growth in renal interstitial fibroblasts.
By flow cytometry analysis (FACS), we determined the varia-
tion of the cell cycle and cell size induced by Ang II. To obtain a
quiescent state (G0), cells were maintained for 48 hours in
serum-free medium. After treatment with iO M Ang II for 24
hours we observed changes in cellular DNA content that reflected
progression through the S phase and mitosis (Fig. 4A). Ang
IT-treated cells presented a high percentage of cells in mitosis
(G2/M + S > GJG1; Fig. 4 A, C). However, the cell size did not
vary in response to the Ang II stimulation (control, 20 10; Ang
II, 24 11; mean channel coefficient of variance, N = 3; P =
NS; Fig. 4B). These data show that when Ang II was added to
quiescent (G0) renal fibroblasts, cells entered G1 and progressed
to S phase.
To further evaluate the effects of Aug 11 on fibroblast growth,
the methylene blue assay was performed. Treatment of growth-
arrested fibroblasts, in a serum-free medium, with io— M Ang II
for 48 hours and 72 hours significantly increased cell proliferation
(Fig. 5A). This effect was dose-dependent between io M to 10
M Ang IT (Fig. 5B) with an optimal concentration of i0 M
(167 12% over control, N = 4, P < 0.05, that represents 30%
with respect to that observed with 10% FCS, which was used as
the positive control). These results suggest that Ang II causes
hyperplasia, but not hypertrophy, in renal interstitial fibroblasts,
in the conditions of our study.
Next, we examined the Ang II receptor subtype linked to the
proliferative response. Preincubation for 30 minutes with the AT1
receptor antagonist DUP753 (10 M), and subsequent stimula-
tion with i0 M Ang II for 48 hours, caused a 70% inhibition in
cell proliferation compared to Ang II alone (N = 4, p < 0.05). By
contrast, the AT2 receptor antagonist PD123177 (10—s M) did not
exert any effect (Fig. 5C). Neither DUP753 nor PD123177 alone
significantly affected cell proliferation in nonstimiilatcd cells (Fig.
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Fig. 4. Cell cycle analysis of angiotensin H-stimulated renal interstitial fibroblasts Treatment of rested cells for 24 hours with iO- M Ang II. DNA
was stained with propidium iodide after RNase treatment. Resulting scans are expressed as contour plots. Histogram (A) shows the relationship of the
DNA content (x-axis) versus cell number (y-axis) and (B) shows the DNA content (x-axis) versus cell size (y-axis). (C) The percent of cells in S+G2/M
in relation to total cell population. As a positive control 10% FCS was used. Results are expressed as mean SEM of 3 experiments. < 0.05 versus
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Fig. 5. Mitogenic effect of angiotensin II
in renal interstitial fibroblasts. (A) Time
course of i0— M Ang IT-stimulation. (B)
Dose response after 48 hours of
incubation. (C) Effect of AT1 (DUP753)
and AT2 (PD123177) receptor antagonist
on Ang Il-stimulated (10 M) cells after
48 hours. Cell proliferation was
determined by methylene blue assay. Bars
represent mean SEM of 4 experiments
made in triplicate. P < 0.05 versus
control; #P < 0.05 versus Ang II alone.
5C). These results suggest that Ang Il-induced cell proliferation is
mediated by the AT1 receptor.
Angiotensin II induces the expression of growth-related nuclear
proto-oncogene c-los
Rapid induction of nuclear proto-oncogenes, such as c-fos, is
one of the earliest transcriptional events, and has been associated
with cell proliferation, cellular differentiation, and hypertrophy
[44]. The c-Jbs protein forms part of the AP-1 complex that binds
to the transcription control elements of some genes [45]. in vivo
systemic Ang TI-infusion induces c-fos gene expression in the rat
kidney [46]. In our study, quiescent renal interstitial fibroblasts
were stimulated with iO— M Ang IT for one hour. Afterwards,
RNA was isolated and c-fos mRNA expression analyzed by
Northern blot. Ang II induced a c-fos transcript of 2.2Kb, while
this gene did not appear in cells in quiescent state (G0) (Fig. 6).
Preincubation with the AT1 receptor antagonist (10 6 M), but not
the AT2, abolished Ang TI-induced gene expression (Fig. 6),
suggesting that an AT1 receptor-dependent mechanism is in-
volved.
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Fig. 7. Angiotensin H increases extracellular matrix gene expression in renal interstitial fibroblasts. (A) Time-course evolution of Ang II action. Cells
were incubated for 0 to 24 hours with io al Ang II. (B) Dose-response of Ang II stimulation after 24 hours. The membranes were hybridized with
eDNA probes of fibronectin (FN), type IV collagen [(al)IV], type I collagen [(al)I] and 28S. A representative Northern blot of 3 blots is shown.
Angiotensin II stimulates gene expression of extracellular
matrix proteins
Many reports have demonstrated that fibroblasts are a major
source of extracellular matrix [3]. We initially evaluated the effect
of Ang II on the message levels of some matrix proteins.
Stimulation of growth-arrested fibroblasts with Ang II for 18 to 24
hours increased the steady-state mRNA levels of fibronectin (FN)
and type I collagen compared to control cells. These effect was
dose-dependent, with a maximal response at i0 M Ang 11(2.5-
and 1.5-fold increase vs. control, after 18 and 24 hr, respectively).
By contrast, there was no effect on type IV collagen mRNA
expression (Fig. 7).
Angiotensin II increases fibronectin production, via protein
kinase C and tyrosine kinases
We assessed the changes in FN production by metabolic
labeling with [3551-Methionine and immunoprecipitation with
anti-FN antibodies. We have observed that most of the FN
produced by renal fibroblasts in normal conditions is secreted to
the extracellular medium (around 70% of total FN). Treatment of
resting fibroblasts with Ang II (10—v to lO M) for 24 hours
caused a significant increase in FN production, with a maximal
response at i0 M Ang 11(165 12% increase vs. control 100%
11, N = 9; P < 0.05; Fig. 8A). In addition, the relationship
between soluble and cell-associated fraction was modified show-
ing an increase in cellular FN production (control, 70% soluble vs.
30% cell-associated; Ang II, 47% vs. 53%).
In adult rat cardiac fibroblasts, Ang LI appears to stimulate
collagen synthesis by both AT1 and AT2 receptors [471. Therefore,
we also evaluated the receptor involved in Ang IT-induced FN
production. As shown in Figure 8B, preincubation with the AT1
receptor antagonist DUP753 (106 M), but not with the AT2
receptor antagonist PD123177 (10 M), inhibited Ang IT-induced
FN synthesis (DUP753, 95% inhibition vs. Ang II alone, N =6,
P < 0.05; PD123177, 30% inhibition, N = 6, P = NS). Neither
DUP753 nor PD123177 alone significantly affected FN synthesis
(Fig. 8B). These results suggest that Ang II regulates matrix
accumulation through the AT1 receptor.
To elucidate the mechanism of Ang II effect on FN production,
we studied the role of the de novo RNA and protein synthesis. As
shown in Figure 8C, pretreatment of cells with actinomycin D
(ActD, 50 tgIml) and cycloheximide (CHX, 1 JLg/ml), inhibitors
of RNA and protein synthesis, respectively, markedly reduced the
amount of FN in control conditions and in response to iO M
Ang 11 stimulation (approximately 65% and 70% inhibition vs.
control, respectively, N = 3, P < 0.05). These data suggest that FN
synthesis induced by Ang IT in renal interstitial fibroblasts is
regulated at the transcriptional level.
To clarify the intracellular mechanism of Ang II effects on FN
synthesis, we detemiined the role of some signaling events. We
wondered whether activation of PKC and tyrosine were involved.
Recently, it has been demonstrated that PKC activation can induce
FN production [48]. Also, Ang II activates PKC in several cell types
[40, 421. In renal interstitial fibroblasts, treatment with the phorbol
ester PMA, an activator of PKC, increased FN production (176
15% increase vs. control, N = 3, P < 0.05; Fig. 8D). The preincu-
bation with the inhibitor of FKC, staurosporine (Staur., 10_8 M) for
one hour, significantly diminished (N = 3, P < 0.05) the Ang
Il-induced FN production (Fig. 8D). Treatment with staurosponne
(10 M) did not affect cell viability. These results indicate that Ang
11 increases FN through a PKC dependent pathway.
We also studied the role of tyrosine kinases in fibroblasts in
response to Ang IT. Cells were preincubated for 30 minutes with
the inhibitor of tyrosine kinase, genistein (Genist, 106 M), before
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Fig. 8. Fibronectin synthesis induced by angiotensin II in renal interstitial fibroblasts. Cells were metabolically labeled with 35S-Methionine and
stimulated for 24 hours. Experimental details are given in the Methods section. (A) Dose-response of Ang II stimulation. (B) Effect of AT1 (DUP753)
and AT2 (PD123 177) receptor antagonist on Ang TI-stimulated cells. (C) Effect of the inhibitors of protein and RNA synthesis (CHX is cycloheximide;
ActD is actinomycin D) on Ang II. (D) Role of PKC and tyrosine kinase inhibitors (staur. is staurosporine, and genist., genistein) in Ang Il-induced
FN production. Upper panels show the densitometric analysis of the FN-bands and the lower panels show a representative autoradiography of
PAGE-SDS of FN. Data are shown as percentage of increase versus control in arbitrary units, and are the mean SEM of 6 to 9 experiments. *D <
0.05 versus control. #P < 0.05 versus Ang II.
Ang II stimulation. As shown in Figure 8D, tyrosine kinase responsible for the FN production observed upon Ang 11 stimu-
inhibition caused a significant reduction in FN synthesis (N = 3, lation.
P < 0.05). These result suggest that tyrosine phosphorylation may We first examined the effect of Ang II on TGF-f3 expression by
participate in Ang TI-induced FN production. Northern blot analysis. Stimulation of quiescent cells with 10 M
Ang II increased the mRNA levels of TGF-J31 with a maximal
Role of TGF. in matrix synthesis elicited by angtiotensin H peak at six hours of incubation (2.3-fold; Fig. 9A). The response
Since TGF-J3 is the major cytokine involved in matrix regulation to Ang TI was markedly attenuated by the AT1 receptor antagonist
[20], we tested the hypothesis that endogenous TGF-J3 may he DUP753 (Fig. 98). Stimulation of renal interstitial fibroblasts with
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Fig. 9. Angiotensin II increased TGF-131 mRNA expression in renal
interstitial fibroblasts. (A) Time-course of Ang II. (B) Role of AT1
receptors. Cells were stimulated with iO M Ang II alone or in the
presence of DUP753 or PD123177. Figures show a representative
Northern blot of 3 that were done. (C) Role of TGF-13 in Ang II-
induced fibronectin (FN) synthesis. Cells were metabolically labeled
and stimulated for 24 hours with iO— M Ang II alone or coincubated
with anti-TGF-3 antibody; 50 M TGF-f3 was used as the positive
control. In the upper part of panel C, densitometric analysis of the
FN bands is shown and the lower part is a representative
autoradiography of PAGE-SDS of FN. Data are shown as a
percentage of the increase versus control values in arbitrary units;
data are the mean SEM of 3 experiments. *p < 0.05 versus control.
#P < 0.05 versus Ang II.
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TGF-f3 (50 pM) increased FN production (220 18% increase vs.
control, N = 3,P < 0.05), with a higher response than Ang II (Fig.
9C). In the presence of neutralizing anti-TGFI3 antibody (10
ig/ml), the Ang TI-induced increase in FN production was totally
abolished (N = 3, P < 0.05; Fig. 9C). This effect appears to be
specific since normal rabbit IgG failed to inhibit the Ang II-
stimulated FN synthesis (not shown). Neither anti-TGFf3 antibody
alone nor control IgG had any effect on FN synthesis. This result
suggests that endogenous TGF-/3 mediates the Ang II effect on
FN synthesis in renal interstitial fibroblasts.
Renal interstitial fibroblasts express angiotensinogen mRNA
levels: Regulation by angiotensin II
By RT-PCR, we observed that interstitial fibroblasts expressed
angiotensinogen mRNA in a constitutive manner (Fig. 10). This
suggests that those cells could participate in the Ang II production
in the kidney. It has been shown that Ang II increases angio-
tensinogen mRNA in rat liver [49] and in cardiac myocytes [50].
We have observed that angiotensinogen gene expression is up-
regulated by Ang 11(1.6-fold, after 6 hr; Fig. 10). This activation
was completely inhibited by DUP753, but unaffected by
PD123177 (Fig. 10).
DISCUSSION
In this paper we approached the idea that Ang II may partici-
pate in the pathogenesis of remodeling and fibrosis of renal
interstitium by stimulating fibroblasts in a direct manner, The
major findings of our work are: (a) Renal interstitial fibroblasts
possess angiotensin receptors, mainly of the AT1 subclass, linked
to calcium mobilization. (b) Ang II induces growth-related events
in fibroblasts such as hyperplasia, matrix accumulation and
TGF-p synthesis through the AT1 receptor. (c) The activation of
PKC and tyrosine phosphorylation may be involved in Ang II
signaling. (d) Renal interstitial fibroblasts express angiotensino-
gen mRNA, which is up-regulated by Ang II.
Angiotensin II binds to specific high-affinity receptors on the
surface of responsive cells. Most of physiological responses of Ang
II, like vessel contraction, calcium release and growth-related
events, are mediated by the AT1 receptor [51]. However, recent
studies suggest that the AT2 receptor is involved in the control of
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cell differentiation [52], apoptosis [531, thropic effects on vascular
smooth muscle cells [54], mononuclear cell recruitment [55, 56]
and natriuretic response [57]. Moreover, an overexpression of
AT2 receptor has been observed during tissue damage [581. In the
adult kidney, the AT1 receptor is present in mesangial, tubular
and interstitial cells [7, 32, 39], while the AT2 receptor is more
abundant in fetal kidney [59]. In this paper we have observed that
rat renal interstitial fibroblasts (NRK49F cell line) possess binding
sites for Ang II, mainly of the AT1 receptor subtype, and express
the mRNA for this receptor. This AT1 receptor presents a similar
Kd to that found other cells, including fibroblasts of different
tissues (cardiac and skin) as well as mesangial and vascular
smooth muscle cells [33—391-
In general, the AT1 receptor is linked to the calcium-phospho-
lipid-dependent signaling pathway. In renal interstitial fibroblasts,
we observed that the Ang II receptor is coupled to calcium
release, both from intracellular stores and across the membrane,
keeping a similar behavior to cardiac fibroblasts and mesangial
cells, but different from tubuloepithelial cells and fetal skin
fibroblasts [35—371 In these latter cells, the AT1 receptor stimu-
lates cAMP production, in contrast to other cells in which it is
coupled to adenyl cyclase in an inhibitory manner [601.
Several investigators, including ourselves [611, have observed
that Ang H induces hyperplasia/hypertrophy in mesangial cells,
while it causes only hypertrophy in tubular epithelial cells [7, 181.
In this study we have demonstrated that Ang IT caused modifica-
tion in the cell cycle in growth-arrested fibroblasts (serum-free
medium), inducing the entry into G1 phase. Also, after 48 hours of
incubation Ang II significantly increased fibroblast proliferation
mediated by AT1 receptor. Furthermore, stimulation for one hour
with Ang II induced c-fos gene expression, one of the earliest
transcriptional events associated with cell growth [44]. Indirect
evidence suggested that Ang II could modify the response of
interstitial renal fibroblasts. The systemic infusion of Ang II into
normal rats markedly up-regulated a-smooth muscle actin expres-
sion in the interstitium, indicating that Ang II may promote the
phenotypic modulation of fibroblasts or expand the specific
population of major fibroblasts [16, 17]. Our results therefore
suggest that in renal interstitial fibroblasts, Aug II, via AT1
receptors, activates short- and long-term growth-related meta-
bolic events.
Interstitial fibrosis occurs in progressive renal diseases. The
progression to end-stage renal failure is determined more by the
degree of tubulointerstitial injury than the extent of glomerular
damage. Fibroblasts from human kidneys with interstitial fibrosis
proliferate and synthesize more collagen types I, III and V, and
FN than fibroblasts from healthy kidneys [621. Several studies
suggest that Ang II may be involved in the accumulation of
extracellular matrix in the kidney [63]. In this sense, in vivo
infusion of Ang II causes interstitial fibrosis, characterized by
deposition of collagens and FN [16, 17]. Also, the administration
of angiotensin converting enzyme (ACE) inhibitors and AT1
receptor antagonist reduces collagen and FN expression and
synthesis in animal models of progressive renal disease [9—12].
There is, however, no evidence of a direct effect of Ang II on
interstitial fibroblasts. Two different renal cells participate in the
development of interstitial fibrosis, tubulo-epithelial cells and
fibroblasts, being the latter the main effector cell of this process
[2]. In cultured proximal epithelial cells Ang II induces hypertro-
phy and stimulates the synthesis of type IV collagen, but not type
I collagen [411. Our in vitro data show that the interaction of Ang
II with renal interstitial fibroblasts increased cell proliferation and
the steady state levels of extracellular matrix proteins (mainly FN
and type I collagen). These results suggest that local Ang II, acting
on both cell types, could contribute to interstitial fibrosis, charac-
terized by tubular atrophy, fibroblast proliferation and matrix
accumulation.
TGF-f3 plays a key role in the pathogenesis of renal injury,
leading to fibrosis and renal dysfunction in several kidney diseases
[19]. TGF-13 contributes to extraeellular matrix accumulation by
increasing matrix production, inhibiting its degradation and mod-
ulating cell-integrin receptors [20]. An interrelationship between
Aug II and TGF-/3 has been described [7]. In vivo Ang II infusion
increased glomerular TGF-p production [64], and in vitro several
cell types, including mesangial and tubular cells, respond to Ang
II stimulation by increasing TGF-13 expression and synthesis [64,
411. Moreover, in experimental models of renal injury, the treat-
ment with ACE inhibitors and AT1 receptor antagonist dimin-
ished renal TGF-/3 expression [11, 12]. In this work we have
demonstrated that in renal interstitial fibroblasts Ang II, via AT1
receptors, increased TGF-pl mRNA expression. Also, the fact
that neutralizing antibody against TGF-f3 abolished the FN syn-
thesis induced by Ang II in these cells suggests that the autocrine
production of TGF-13 is involved in Ang 11-induced matrix accu-
mulation.
The effects of Aug II on growth, gene expression and FN
production are mediated primarily by AT1 receptor. DUP753
completely blocked Ang II effects, whereas AT2 receptor antag-
onist did not interfere with these Aug II responses. These results
support recent data that AT1 receptor antagonist are as effective
as ACE inhibitors in reducing interstitial damage in renal disease
[12], and suggest that this beneficial effect could he due to the
modulation of Ang II responses (cell proliferation and synthesis of
matrix proteins and TGF-f3) in interstitial fibroblasts.
We further investigated some mechanisms in response to Aug
II stimulation in renal interstitial fibroblasts. We have observed
GAPDH
Ao
Fig. 10. Demonstration of angiotensinogen gene expression in renal
interstitial fibroblasts. Renal fibroblasts constitutively express angio-
tensinogen (Ao) mRNA as shown by RT-PCR. Cells were stimulated for
six hours with 10 M Ang II alone or in the presence of DUP753 or
PD123177. A representative experiment of 3 RT-PCR is shown; G3PDH
was used as the internal control.
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that in these cells, AT1 receptors are linked to calcium mobiliza-
tion by a mechanism dependent of PKC and tyrosine kinase
activation. Binding of Ang II to AT1 receptor increases protein
tyrosine phosphorylation and activates several protein kinases,
such as PKC, MAP kinase, calcium calmodulin-dependent kinase
and S6 kinase [42, 43]. Numerous studies suggest an important
role for PKC as an intracellular mediator of the effects of some
hypertrophic growth stimuli [651, including EN production [481. In
this work, we have observed that Ang Il-induced calcium mobili-
zation and EN production was inhibited by staurosporine, a PKC
inhibitor, suggesting that activation of PKC is involved in Ang II
responses. Specific phosphotyrosine-containing proteins have
been identified as substrates for Ang Il-stimulated tyrosine ki-
nases, including PLC-yi [66] and STAT family of transcription
factors [67]. Recent studies in vascular smooth muscle cells
suggest that many Ang II effects require tyrosine phosphorylation,
such as vessel contraction, inositol triphosphate formation, pro-
tein synthesis and MAP kinase activity, as shown by the employ-
ment of tyrosine kinase inhibitors [43, 68, 69]. In this work, we
have shown that Ang lI-induced calcium mobilization and FN
synthesis were blocked by genistein, a tyrosine kinase inhibitor.
Although the AT1 receptor is a typical G protein-coupled recep-
tor that lacks tyrosine kinase activity, these results suggest that a
receptor-associated tyrosine-kinase may be involved in Ang II
signaling. All these results contribute to elucidate the role of
tyrosine kinases in Ang II actions in renal cells.
Another major finding of our study was that renal interstitial
fibroblasts showed constitutive angiotensinogen mRNA, suggest-
ing that those cells could possess intracellular renin-angiotensin
system and therefore contribute to local Ang II generation. These
data are in agreement with studies on cardiac fibroblasts that
present intracellular Ang I, Ang II and ACE immunoreactivity
[70]. Although future studies are necessary to determine whether
all components of this system, like renin and ACE activity, are
present in renal fibroblasts, increasing evidence suggests that
these cells could contribute to local Ang II generation. We have
also observed that angiotensinogen gene expression was up-
regulated in response to Ang 11, thus showing a positive feedback
regulation. A similar phenomenon has previously been observed
in hepatocytes and cardiac myocytes [50, 711. Activation of the
transcription factor NF-KB could be involved in the regulation of
angiotensinogen mRNA levels in hepatocytes [72]. Recent data
have shown the activation of transcription factors during tissue
damage [73]. Also, elevated angiotensinogen mRNA levels have
been observed in those situations [74]. In this sense, in a model of
immune complex nephritis, we have recently demonstrated an
increase in NF-KB activity in renal cortex [75] coincidentally with
an increase in cortical ACE activity and an up-regulation of renal
angiotensinogen mRNA expression [15].In addition, we have also
demonstrated that Ang II activates NF-KB in cultured glomerular
mesangial cells and vascular smooth muscle cells [75, 76]. There-
fore, it is reasonable to speculate that Ang Il-induced angio-
tensinogen gene in renal interstitial fibroblasts could be mediated
by activation of NF-KB. All these data suggest that these cells are
not only a target of Ang II, but might also contribute to a
sustained synthesis of local Ang II, and therefore potentially to
further tissue damage.
In summary, in this study we have noted that Ang 11 caused
hyperplasia of renal interstitial fibroblasts and increased synthesis
of extracellular matrix, via the AT1 receptor type. Furthermore,
Ang 11 may initiate a positive-feedback regulation of fibroblasts
growth, inducing the expression of TGF-/3l and arigiotensinogen
genes. These results suggest that locally increased Ang II gener-
ation, by direct interaction with fibroblasts, could contribute to the
pathogenesis of interstitial fibrosis.
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